Comparison · NCT05968599-deaths
Abiraterone vs Enzalutamide: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Abiraterone vs Enzalutamide: deaths from any cause. Trial comparisons, record NCT05968599-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05968599-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.765 | 0.742 | 0.787 | wilson | |
| Risk in group 2 | 0.732 | 0.708 | 0.755 | wilson | |
| Risk difference, group 1 minus group 2 | 0.033 | 0.000451 | 0.0654 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 1 | 1.09 | log | |
| Odds ratio, group 1 over group 2 | 1.19 | 1 | 1.42 | log | |
| Number needed to harm, for one more death from any cause on Abiraterone than on Enzalutamide | 30.3 | 15.3 | 2,220 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Abiraterone | Participants diagnosed with mCRPC who initiated abiraterone, in real-world setting under routine clinical practice were included. Data from these participants were observed retrospectively. No intervention was administered during this study. | 1,007 | 1,316 | EG000 |
| Group 2 | Enzalutamide | Participants diagnosed with mCRPC who initiated enzalutamide, in real-world setting under routine clinical practice were included. Data from these participants were observed retrospectively. No intervention was administered during this study. | 1,036 | 1,415 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
- NCT number
- NCT05968599
- Phases
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Enzalutamide, Abiraterone acetate
- Lead sponsor
- Pfizer
- Results first posted
- 2026-02-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05968599?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05968599-deaths